Dr Ross Is Zbar, MD | |
6600 Van Aalst Blvd, Fort Benning, GA 31905-2102 | |
(762) 408-2273 | |
Not Available |
Full Name | Dr Ross Is Zbar |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 6600 Van Aalst Blvd, Fort Benning, Georgia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912996885 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | MA68991 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Ross Is Zbar, MD 1201 Front Ave Unit 515, Columbus, GA 31901-5235 Ph: (201) 207-1905 | Dr Ross Is Zbar, MD 6600 Van Aalst Blvd, Fort Benning, GA 31905-2102 Ph: (762) 408-2273 |
News Archive
The Carlsberg Foundations Research Prizes 2012 goes to Professor in molecular biology Kristian Helin and Professor in international politics Ole W-ver. Each researcher receives 1 million DKK where - should be spend on further research.
In a breakthrough for understanding brain evolution, neuroscientists have shown that differences between primate brains - from the tiny marmoset to human - can be largely explained as consequences of the same genetic program.
In a new report published in the Journal of Leukocyte Biology, scientists lay the groundwork for the development of novel tumor therapies that may help rid the body of cancer by inhibiting the recruitment of a specific suppressive immune cell type called "regulatory T-cells." The approach described in the report shows that an immune molecule, called interleukin-27, promotes the recruitment of regulatory T-cells.
Intravitreal ranibizumab treatment for age-related macular degeneration does not elevate the risk of mortality, suggests a meta-analysis published in Ophthalmology.
Ablative Solutions, Inc. (ASI), a privately held company headquartered in Kalamazoo, MI, with offices in Palo Alto, CA, announced today that Professors Wojtek Wojakowski and Mariusz Hochul have treated the first two patients in the European Peregrine Post-Market Study.
› Verified 5 days ago